AUTHOR INDEX: 1984 (Vol. XXI)

Page numbers referring to 'Book Reviews' are italicized

A

Ahmad N. 63, 349, 361
Arsenio L. 357
Ascari E. 193
Assal J. P. *295*
Attardo-Parrinello G. 193
Avogaro P. 315

B

Bansal R. 63
Baraldi A. 257
Bardin C. W. *202*
Barosi G. 257
Bartoli U. 251
Bartolomei G. 251
Bay U. 303
Beck B. 325
Belfiore F. *97, 295*
Bellomo G. 257
Berger M. *295*
Bittolo Bon G. 315
Bonora E. 241, 375
Bose S. M. 203
Bota B. 387
Brambilla G. 193
Brown A. 333
Bruno G. 289
Butturini U. 241, 375
Buzzelli G. 241

C

Canivet J. *295*
Capito K. 365
Castelli M. R. 71
Cavalié G. 211
Cavalli-Sforza L. T. 357
Cazzola M. 257
Cazzolato G. 315
Ceriello A. 49, 281
Chérié-Lignière E. L. 193
Chopra A. 141
Ciavarella A. 275
Cignarelli M. 161
Cohen P. 181
Collini P. 71
Colombo F. 71
Cooperstein S. J. *97*
Coradello H. 123
Coraggio S. 235
Coscelli C. 241, 375
Cospite M. R. 161
Curcio F. 49

D

Dambay A. 115
Debry G. 325
De Giorgio L. A. 251
Delfino M. 289
Dello Russo P. 49

De Maria R. 71
Di Pinto P. 281
Ditzel J. 167
Dix D. 181
Dobrilla G. *201*
Dollet J.-M. 325
Drouin P. 325
Dunbar J. C. 333, 341

E

Ellenberg M. *296*
Emanuele R. 357
Eschwege E. *98*

F

Flammini M. 275
Fratino P. 257
Freinkel N. *98*
Freitas J. P. 133
Froesch E. R. 303

G

Galuppi V. 275
Garrido D. 219
Gay N. *295*
Gentilini P. 241
Giorgino R. 161
Gironi A. 251
Giugliano D. 49, 281
Giunta R. 281
Giunti A. 275
Gnudi A. 357
Gort E. 153
Gotto A. M. *98*
Grandillo F. 281
Guastamacchia E. 161
Güell R. 153

H

Habenicht A. J. R. *98*
Hanson M. 173
Hanson U. 55
Hedeskov C. J. 365
Hoskins B. 263

I

Iandoli R. 289
Iannello S. *295*
Illiano G. 49

J

Janzon L. 173
Jensen T. 167
Jurutka K. R. *98*

K

Karmarkar M. G. 141
Keen H. 93, *296*
Khan M. M. 349
Kidwai J. R. 63, 349, 361
Köbberling J. *201*
Krieger D. T. *202*
Krishna Ram B. 141

L

Landt J. 365
Laron Z. 35
Laurell P. 173
Legrain M. *296*
Levin S. 123
Levy-Cruz F. 133
Liguory C. *201*
Lindell S. E. 173
Lischka A. 123
Lubec G. 123
Lunell N.-O. 55

M

Mammini P. 251
Mann J. I. *297*
Márquez A. 219
Martellotta D. 289
Martino A. P. 257
Martins-Silva J. 133
Más J. 115
Mathur K. B. 361
Matsumoto P. 333
Meyer M. 303
Middelhoff G. *98*

Mirouze J. 211
Misiewicz G. *201*
Mohan R. 85
Mohan V. 85
Mohanam S. 203
Mondola P. 235
Monfrecola G. 289
Monnier L. 211
Montecucco C. 193
Morell B. 303
Moroni A. 275

N

Nardelli G. 161

O

Obi G. O. 105
Oli J. M. 105
Olmi R. 275
Orioli S. 241

P

Padrón R. S. 115
Palestra P. 257
Paolisso G. 49
Patti L. 235
Pérez R. L. 219
Persson B. 55
Pfeiffer E. F. 1
Pointel J. P. 325
Pollak A. 123
Porr O. 303
Pozzoli G. 71
Pyörälä K. *297*

R

Rabuazzo A. *97*
Ramachandran A. 85
Rastogi A. K. 63, 349, 361
Reid H. L. 105
Renauld A. 219
Richard J.-L. 211
Rifkin H. *296*
Robuschi G. 357
Rodier M. 211
Rodríguez R. R. 219
Roti E. 357
Rumboldt Z. 387

S

Sachdev G. 141
Santangelo F. 235
Schettler G. *98*
Schober E. 123
Scognamiglio G. 281
Scott J. M. 263
Seghieri G. 251
Sgambato S. 49
Sharma S. D. 361
Silverstone T. *99*
Sousa-Ramalho P. 133
Spriano P. 257
Stangenberg M. 55
Stefanelli G. 161
Strata A. 357
Suárez R. 115
Susheela L. 85
Sverdlik R. C. 219

T

Tattersall R. *201*
Teuscher A. *297*
Thams P. 365
Torella R. 281
Trell E. 173

V

Valls O. 153
Vannini P. 275
Villaume Ch. 325
Viswanathan M. 85
Vitolo E. 71
Von Lawzewitsch I. 219

W

Waldhauser F. 123
Watkins D. *97*
Wider M. D. 341

SUBJECT INDEX: 1984 (Vol. XXI)

Page numbers referring to 'Book Reviews' are italicized

A

Adipose tissue
in vitro effects of
anti-insulin serum 141

Aldimine eliminator
dialysis 167

Alkaline phosphatase activity
and glucose fluctuation 123
and non-enzymatic glycosylation . 123
and oral glucose tolerance test . . 123
in type I diabetes 123

Agaricus bisporus
and age 349
and insulin release 63, 349
and islets of Langerhans . . 63, 349
PHA-B fraction of 63, 349

Analysis of variance 71, 219, 241
263, 333, 357

Apolipoproteins
and insulin levels 235
and oral glucose load 235
in type I diabetics 315
in type II diabetics 315

Artificial pancreas
and oxygen-release capacity . . 281

Atherosclerosis
a book *98*

B

B-cell function
in maturity-onset diabetes 161

β-glucuronidase
and experimental diabetes . . . 203

β-N-acetyl-glucosamine
and experimental diabetes . . . 203

Bladder disorders
early morning diuresis 153
in diabetic children 153
residual urine 153
studied by echography 153
vesical volume 153

Blood filterability
and glycosylated hemoglobin . . 133
and hemoglobin-oxygen affinity . 133
and retinopathy 133
in diabetic patients 133
microcirculation 133

Bullosis diabeticorum
a case report 289
and peripheral neuropathy . . . 289

C

Calcium
and *Agaricus bisporus* PHA-B . . 63, 349
uptake by islets of Langerhans . 63, 349
urinary excretion 263

Calciuria
and insulin 263
in absence of blood glucose control 263

Chlorpropamide
and cholestatic hepatitis 387
and eosinophilia 387

Cholecystokinin (CCK)
peptides analogues to C-terminal tetrapeptide amide of 361
synthetic analogue 361

Cholesterol
and oral glucose load 235
and plasma fibronectin 251
and serum insulin levels 235
and type I diabetics 315
and type II diabetics 85, 315

Chronic liver disease
and C-peptide 241
and FFA 241
and GH 241
and glucagon 241
and insulin resistance 241
and insulin sensitivity 241

Chronic pancreatitis
and amended IRI/BG ratio . . . 325

Continuous blood glucose monitoring
to study biosynthetic human insulin 211

Continuous i.v. insulin infusion
and microalbuminuria 303
and nerve conduction velocity . . 303
and relative refractory period of nerve conduction 303
hyperglycemic episodes 303
hypoglycemic episodes 303
in type I diabetics 303

Conventional insulin therapy
and microalbuminuria 303
and nerve conduction velocity . . 303
in type I diabetics 303

C-peptide
and chronic liver diseases . . . 241
and duration of disease 375
and insulin requirement 375
and metabolic control 375
in type I diabetics 375

D

Diabetes congresses 1981, 1982
a book *97, 295*

Diabetes mellitus
and bullous eruption 289
and hip replacement 275
and infections 275
and male reproduction 115
and semen analysis in adolescent . 115
a psychosomatic disease 35
classification 93
courting and marriage 35
diagnosis of 93
employment 35
epidemiology
a book *98*
external continuous insulin infusion pump 35
genetics
a book *201*
glycosylated albumin 49
glycosylated hemoglobin . . 49, 167
in epidemiological perspective
a book *297*
management 49
patient education
a book *295*
reviewed congresses of 1981, 1982
a book *97, 295*
theory and practice
a book *296*

Diabetes mellitus in children and adolescent
a psycho-somatic disease . . . 35
blood glucose self-monitoring . . 35
education program 35
family relations 35
group discussion 35
multidisciplinary team approach . 35
psycho-social problem 35
siblings 35
urinary bladder disorders . . . 153

Diabetes surgery
and infections 275

Diabetic angiopathy
and hematocrit 257

Diabetic nephropathy
a book *296*

2,3-Diphosphoglycerate (2,3-DPG)
and artificial pancreas 281
in type I diabetics 281

Dopamine
and glucagon secretion *in vitro* . . 333

Down regulation of insulin receptors
in chronic liver disease 241

Drugs and appetite
a book *99*

E

Echography
in urinary bladder disorders
in young diabetics 153

Endocrinology
current therapy
a book *202*

Epinephrine infusion
and phentolamine 219
and propranolol 219
effects on blood glucose 219
effects on FFA 219
effects on serum insulin 219

Erythrocyte deformability
in diabetics with hypertension . . 105
in Nigerian diabetics 105

Eviscerated rats
and persistent immunoreactive
glucagon 341

Experimental diabetes
and calciuria 263
and glycosaminoglycans 203
and uronic acid 203
induced by alloxan 203
induced by streptozotocin . . . 203

F

Fibronectin (plasmatic)
and cholesterol 251
and diabetic retinopathy . . . 251
and endothelial damage 251
and LDL cholesterol 251
in diabetics 251

Free fatty acids (FFA)
and anti-insulin serum in ketosis-
resistant young diabetics of
northern India 141
in chronic liver diseases 241

G

Gastroduodenal surgery
and oral glucose tolerance test . . 173
and plasma insulin 173
and smoking 173

Gastrointestinal disorders
current therapy
a book *201*

Gestational diabetes
and intermediary metabolites . . 55
neonatal morbidity 55
newborn infants 55

Glibenclamide (glyburide)
in middle-aged diabetic 387

Glucagon
and dopamine 333
and endogenous biogenic amines . 333
and norepinephrine 333
and propranolol 333
and serotonin 333
chemical characterization . . . 341
in chronic liver diseases 241
in eviscerated rats 341
secretion *in vitro* 333

Glucagon-like immunoreactivity
in eviscerated rats 341
its chemical characterization . . 341
of ileal mucosa 341
of submaxillary salivary glands . . 341

Glycerol
and anti-insulin serum in
ketosis-resistant young
diabetics of northern India . . 141

Glycosaminoglycans (GAG)
in experimental diabetes . . . 203

Glycosylated hemoglobin
and artificial pancreas 281
evaluation by aminophenylboronic
acid affinity chromatography . 49
in type I diabetics 49
in type II diabetics 49

labile 49, 167
and metabolic control 49
and reversible affinity chromatography 49
stable 49, 167

Glycosylated proteins
and type I diabetics 49
and type II diabetics 49
evaluation by aminophenylboronic acid affinity chromatography . . . 49
metabolic control 49

Growth hormone (GH)
in chronic liver diseases 241

H

HbA_1 (see Glycosylated hemoglobin)

HDL
in type I diabetics 85, 315
in type II diabetics 315

Hematocrit
and microcirculatory hemoconcentration 257
whole body/venous ratio in diabetics 257

Hemoglobin A_1
aldimine eliminator 167
blood glucose 167
determination with the macrocolumn procedure 167
determination with the microcolumn procedure 167
glycohemoglobin 167
Schiff-base intermediate 167
semicarbazide 167

Hemoglobin-oxygen affinity
and blood filterability 133
in diabetic patients 133

Hip replacement
and diabetics 275
and infections 275

Human (recombinant DNA) insulin
effectiveness 211
hypoglycemic effects 211
in insulin-dependent diabetics . . 211
NPH 211
vs porcine insulin 211

Hypoglycemic episodes from sulfonylurea
fatal 1
non-fatal 1

I

Idiosyncratic hepatotoxic reactions
and chlorpropamide 387
and tolbutamide 387

Insulinoma
and amended IRI/BG ratio . . . 325

Insulin release
after gastroduodenal surgery . . 173
and glyburide 1
and redox state 365
and smoking 173
and tolbutamide 1
by oral hypoglycemic agents . . 1
by peptide analogues of CCK, *in vitro* 361
effects of PHA-B fractions of *Agaricus bisporus* lectin on . . 63, 349
in isolated and perifused islets . . 1
in the presence of glucose . . . 1
with fructose 365
with glucose 365

Insulin resistance
in chronic liver diseases 241

Insulin sensitivity
and metabolic control 375
in chronic liver disease 241
in type I diabetics 375

Intermediary metabolites
in pregnant women with gestational diabetes 55

Iodide administration
and tolbutamide 357
in diabetic patients 357

IRI/BG ratio
during sleep 325
in chronic pancreatitis 325
in diabetics 325
in insulinoma 325
in its amended form 325
in the morning 325
in obese subjects 325

Islets of Langerhans
agaricus bisporus PHA-B on . . 63, 349
and CCK 361
biochemistry, physiology and pathology a book *97*
Isolated islets
and *Agaricus bisporus* PHA-B . . . 349
and glucagon secretion 333

K

Ketosis-prone young diabetics (KPYD)
in northern India 141
Ketosis-resistant young diabetics (KRYD)
effects of i.v. glucose 141
effects of i.v. glucagon 141
effects of s.c. epinephrine . . . 141
in northern India 141
K-value
in ketosis-resistant young diabetics of northern India 141

L

Left ventricular function
B-notch 71
fractional shortening during the first third of the systole 71
in type II diabetic patients . . . 71
mitral opening delay (MOD) . . 71
studied by M mode echocardiography 71
Lipids
and type I diabetics 315
and type II diabetics 315
Low density lipoproteins (LDL) cholesterol
and maculopathy 85
and plasma fibronectin 251
and retinopathy 85, 251
in non-insulin-dependent diabetes . 85
Lysosomal acid hydrolases
and experimental diabetes . . . 203

M

Maculopathy
and LDL cholesterol 85
and lipid metabolism 85
in non-insulin-dependent diabetics 85
Mann-Whitney U test 55
Maturity-onset diabetes
C-peptide 161
duration of residual B-cell function 161
insulin treatment 161
metabolic control 161
sulfonylurea 161
Meningioma
improvement of hyperglycemia and hyperinsulinemia after removal . 193
Metabolism
a book *98*
Microalbuminuria
during continuous i.v. insulin infusion 303
during conventional insulin therapy 303
during rest and exercise 303

N

Neuropathy
and continuous i.v. infusion . . 303
Nigerian diabetes
and erythrocyte deformability . . 105
with hemoglobin genotype HbAA 105
Norepinephrine
and glucagon secretion *in vitro* . . 323

O

Open-loop insulin infusion pump
and microalbuminuria 303
and nerve conduction velocity . . 303
Oral glucose tolerance test (OGTT)
an objective method of interpretation 181
and gastro-duodenal surgery . . 173
and smoking 173
median plasma glucose 181
unimodal distribution of glucose concentration 181
Oral hypoglycemic agents
and glucose induced insulin release 1
and insulin release in the presence of glucose 1
C-peptide 1
experimental studies 1
extrapancreatic action 1
glibornuride 1

glisoxepide 1
glyburide 1
hypoglycemic reactions 1
in clinical therapy 1
in isolated and perifused islets . . 1
in perfused rat pancreas . . . 1
insulin release 1
mechanism of action 1
second generation sulfonylureas . 1
tolbutamide 1

Oxygen release capacity
after artificial pancreas 281
in type I diabetics 281

P

Pancreatic action
of sulfonylureas 1

Pancreatic islet
and ATP 365
and DNA 365
and NAD^+, $NADP^+$ 365
and phosphoenolpyruvate . . . 365
and pyridine nucleotides . . . 365
and redox state 365

Pearson's correlation coefficient . . . 375

Plasma fibrinogen
in Nigerian diabetics 105

Pregnant women with gestational diabetes
and glucose 55
and glycerol 55
and 3-hydroxybutyrate (3HB) . . 55
and intermediary metabolites . . 55
and metabolic profiles 55
and neonatal morbidity 55
and newborn infants 55
and non-esterified fatty acids (NEFA) 55
treatment with diet 55
treatment with insulin 55

Propranolol
and glucagon secretion *in vitro* . . 333

R

Red blood cells
in type I diabetics 281
oxygen release capacity 281

Relative refractory period of nerve conduction
during continuous i.v. insulin infusion 303
during conventional insulin therapy 303

Renal calcium transport
and insulin 263

residual B-cell function
and duration of disease 375
and indices of metabolic control . 375
its relation with clinical features . 375
in type I diabetics 375

Retinopathy
and plasma fibronectin 251

S

Semen analysis
and diabetic neuropathy . . . 115
and diabetic retinopathy . . . 115
and plasma testosterone 115
in diabetic adolescent 115

Serotonin
and glucagon secretion *in vitro* . . 333

^{35}S-sulfate incorporation
in experimental diabetes . . . 203
in kidney 203
in liver 203
in skin 203

Student's t-test 49, 85, 105, 115, 123, 133, 141, 173, 203, 211, 219, 241, 251, 257, 263, 281, 357

Sulfonylureas
glucagon inhibiting action . . . 1
potentiation of glucose action . . 1
second generation 1

Synthetic analogue
of cholecystokinin 361

T

Thyroid function
and iodide administration . . . 357
and tolbutamide 357
in diabetic patients 357

Thyroxine
and pancreatic cytology 219

Tolbutamide
and cholestatic hepatitis 387
and iodide administration . . . 357
and systemic manifestation of idiosyncratic reactions . . . 387
and thyroid function 357

Triglycerides
and insulin levels 235
and oral glucose load 235
and type I diabetics 315
and type II diabetics 85, 315

Type I diabetics
and cholesterol 315
and C-peptide 375
and HDL 315
and insulin sensitivity 375
and lipids 315
and triglycerides 315
and VLDL 315

Type II diabetics
and amended IRI/BG ratio . . . 325
and iodide administration . . . 357
and thyroid function 357
HDL cholesterol in 85, 315
LDL cholesterol in 85
LDL/HDL cholesterol ratio in . . 85
left ventricular function in . . . 71
lipid metabolism in 85, 315
total/HDL cholesterol ratio in . . 85
triglycerides in 85, 315
VLDL in 315

V

Very low density lipoproteins (VLDL)
in type I diabetics 315
in type II diabetics 315

W

Werner's syndrome
hyperinsulinemic diabetes . . . 193
meningioma 193